SOLOSEC is generally well-tolerated and delivers a complete course of therapy with one oral dose1
In pivotal trials for the treatment of BV, side effects were mild or moderate in intensity and nonserious.2,3
* 29% of patients on SOLOSEC experienced side effects in pivotal trials.
SOLOSEC has no pregnancy restrictions1
Available data on pregnancy are limited to animal studies.1
Metronidazole and tinidazole are contraindicated in the first trimester of pregnancy.4,5
Pregnant women with untreated or inadequately treated BV are at increased risk for complications, including to the infant.6,7
Pregnant women with untreated or inadequately treated BV are at increased risk for complications, including to the infant.6,7

SEE BV MANAGEMENT CHALLENGES
References:
1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2021. 2. Muzny CA, Schwebke JR, Nyirjesy P, et al. Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study. Clin Infect Dis 2021. 3. Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2017;130(2):379-386. 4. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis [published correction appears in Am J Obstet Gynecol 2018;219(1):110]. Am J Obstet Gynecol 2017;217(6):678.e1-678.e9. 5. Flagyl [prescribing information]. New York, NY: Pfizer; 2021. 6. Tinidazole Tablets [prescribing information]. Buffalo Grove, IL: G.D. PACK Pharmaceuticals, LLC; 2018.